Trial Profile
A prospective study to predict the reversibility of cardiotoxicity caused by trastuzumab immunotherapy in non-meta-static breast cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 19 Dec 2015 New trial record